We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (GMAIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01221246
First Posted: October 14, 2010
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
University of California, Los Angeles
Huntington Hospital
Hoag Memorial Hospital Presbyterian
Columbia University
California Pacific Medical Center Research Institute
University Hospital Erlangen
Sarasota Memorial Hospital
University of Louisville
Information provided by (Responsible Party):
Genervon Biopharmaceuticals, LLC
October 11, 2010
October 14, 2010
August 2, 2017
March 8, 2011
July 7, 2016   (Final data collection date for primary outcome measure)
Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint [ Time Frame: Day 90 ]
NIH Stroke Scale is a standardized neurological examination intended to describe the neurological deficits found in large groups of stroke patients participating in treatment trials. Percent change from baseline in NIHSS is calculated and compared.
  • Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint [ Time Frame: Day 90 ]
    NIH Stroke Scale is a standardized neurological examination inteneded to describe the neurological deficits found in large groups of stroke patients participating in treatment trials. Percent change from baseline in NIHSS is calculated and compared.
  • Compare the safety and tolerability of GM602 with placebo in a population of patients with moderate to severe impairment following acute ischemic stroke as primary safety endpoint. [ Time Frame: Day 90 ]
    Safety and tolerability issues include: adverse events, hemorrhage, neurological deterioration, seizure, respiratory compromise
Complete list of historical versions of study NCT01221246 on ClinicalTrials.gov Archive Site
  • Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 30 ]
    Percent change in NIHSS from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo
  • Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 90 ]
    The Barthel Index is measured using both historical and direct observational information. It measures self-care and mobility and will help define the degree of residual disability. Percent change from baseline in BI is calculated.
  • Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 30 ]
    Percent change in BI from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo
  • Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days [ Time Frame: Day 90 ]
    compared with placebo at each modified Rankin Scale (mRS) level at 90 days.
  • Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days [ Time Frame: Day 30 ]
    compared with placebo at each modified Rankin Scale (mRS) level at 30 days.
  • Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo [ Time Frame: Day 90 ]
    all cause mortality data through 3 months
  • Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 30 ]
  • Functional Outcome as measured by the difference in percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 90 ]
    The Barthel Index is measured using both historical and direct observational information. It measures self-care and mobility and will help define the degree of residual disability. Percent change from baseline in BI is calculated.
  • Functional Outcome as measured by the difference in percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo [ Time Frame: Day 30 ]
  • Efficacy as measured by Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days [ Time Frame: Day 90 ]
    The Modified Rankin Scale is the most commonly used global scale. It is a simple overall measure of independence that allows comparisons between patients with different kinds of neurologic deficits, and it also helps to evaluate recovery.The best possible score is 0; the worst is 5. Number of patients at each mRS level are summarized in a table.
  • Efficacy as measured by Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days [ Time Frame: Day 30 ]
  • Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo [ Time Frame: Day 90 ]
Primary Safety Endpoints [ Time Frame: througyh 3 months ]
Adverse events, Fatal ICH. nonfatal symptomatic parenchymal hemorrhage, or other symptomatic 1CH, Neurological deterioration during hospitalization, Number of seizures after stroke, Respiratory compromise as observed by respiratory rate
Not Provided
 
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window
The purpose of this research study is to determine whether the investigational drug GM602, is effective and safe in the treatment of ischemic stroke (strokes caused by a blood clot blocking the flow of blood through one, or more of the blood vessels supplying the brain) when administered up to 18 hours after symptoms begin.
Stroke is a serious and life threatening disease. About 85% of all strokes are ischemic, caused by a blood clot or plaque that blocks a blood vessel in the brain. The thrombolytic drug tissue plasminogen activator (tPA) is the only early treatment for acute ischemic stroke approved by the FDA. Treatment with tPA must be administered within three hours of the stroke onset. Furthermore, tPA treatment carries a recognized risk of bleeding in the brain. GM602 is an investigational drug that may act as a neuroprotectant in patients who have had a stroke. It is thought to stop cell death and reduce inflammation in the injured area of the brain. This study is designed to evaluate the safety and efficacy of GM602 administered intravenously to patients in three consecutive daily doses of 320 mg/dose or 480 mg/dose, the initial dose administered within 18 hours after onset of acute ischemic stroke in the Middle Cerebral artery region.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Stroke
  • Drug: GM602
    First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
    Other Names:
    • GM6
    • GM604
    • GM608
    • MNTF
  • Drug: Placebo Comparator
    First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
    Other Name: Bacteriostatic saline
  • Experimental: GM602
    First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
    Intervention: Drug: GM602
  • Placebo Comparator: Placebo Comparator
    First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
    Intervention: Drug: Placebo Comparator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
34
July 7, 2016
July 7, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 18 years old
  • Be eligible for MRI or CT scan
  • Have suffered acute ischemic stroke in the middle cerebral artery (MCA) distribution, as verified by the Screening DWI abnormality and Screening PWI abnormality
  • Have NIH Stroke Scale (NIHSS) score total score of 9-20 inclusive at screening
  • Have suffered acute ischemic stroke within 18 hours
  • Have been functionally independent with a Modified Rankin Score (mRS) of 0 or 1 prior to suffering stroke
  • Patients who received tPA or FDA approved mechanical device can also enroll
  • completed informed consent form

Exclusion Criteria:

  • Have history of stroke in the past 3 months
  • Cannot be evaluated using MRI/CT
  • Have stroke of the brainstem or cerebellum
  • Have clinical presentation consistent with acute MI by EKG criteria (STEMI) at screening
  • Have hemorrhage revealed by CT or MRI scan
  • Have > 1/3 MCA territory HYPER intensity as seen on MRI OR >1/3 MCA territory HYPO intensity as seen on CT
  • Have blood sugar level >400 mg/DL or<50 mg/dL
  • Have kidney disease, creatinine > 2.0
  • Have had recent (within 90 days) serious head trauma or head trauma with loss of consciousness
  • Have any prior history of seizure
  • Have clinically relevant pre-existing neurological deficit (Historical Rankin score ≥ 2)
  • Have any other known clinically significant medical disorder (cardiovascular, hepatic, renal, endocrine, respiratory, immunological, cancer, AIDS)
  • Life expectancy of less than 6 months due to comorbid conditions
  • Women of child bearing potential who are pregnant or breast-feeding or unable to practice birth control during the study period
  • Have participated in any other trial of an investigational agent within 90 days prior to screening
  • Informed consent cannot be obtained
  • Unable to participate in study visits
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01221246
GEN-002
No
Not Provided
Not Provided
Genervon Biopharmaceuticals, LLC
Genervon Biopharmaceuticals, LLC
  • University of California, Los Angeles
  • Huntington Hospital
  • Hoag Memorial Hospital Presbyterian
  • Columbia University
  • California Pacific Medical Center Research Institute
  • University Hospital Erlangen
  • Sarasota Memorial Hospital
  • University of Louisville
Principal Investigator: Arbi G Ohanian, MD Huntington Memorial Hospital
Principal Investigator: Sidney Starkman, MD UCLA Stroke Center
Principal Investigator: Jeff Saver, MD UCLA Stroke Center
Principal Investigator: David Brown, MD Hoag Memorial Hospital Presbyterian
Principal Investigator: Stephan A Mayer, M.D. Columbia University
Principal Investigator: Nobl Barazangi, M.D. California Pacific Medical Center Research Institute
Principal Investigator: Thomas G Devlin, M.D. University Erlanger Hospital
Principal Investigator: Mauricio Concha, M.D. Sarasota Memorial Hospital
Principal Investigator: Anand Vaishnav, M.D. University of Louisville
Genervon Biopharmaceuticals, LLC
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP